Up-to-date tools for risk assessment before allogeneic hematopoietic cell transplantation (Q38858092)

7 September 2017

1 reference

title

Up-to-date tools for risk assessment before allogeneic hematopoietic cell transplantation (English)

1 reference

7 September 2017

M Elsawy

1

1 reference

7 September 2017

M L Sorror

series ordinal

2

1 reference

7 September 2017

language of work or name

English

0 references

publication date

6 June 2016

1 reference

Bone Marrow Transplantation

7 September 2017

published in

1 reference

7 September 2017

volume

51

1 reference

7 September 2017

issue

10

1 reference

7 September 2017

page(s)

1283-1300

1 reference

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

7 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038/BMT.2016.141

A disease risk index for patients undergoing allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/BMT.2016.141

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/BMT.2016.141

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/BMT.2016.141

Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow Transplant Research Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/BMT.2016.141

Multi-centre validation of the prognostic value of the haematopoietic cell transplantation- specific comorbidity index among recipient of allogeneic haematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/BMT.2016.141

Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index: a prospective, multicenter GITMO study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/BMT.2016.141

Comparable antileukemia/lymphoma effects in nonremission patients undergoing allogeneic hematopoietic cell transplantation with a conventional cytoreductive or reduced-intensity regimen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/BMT.2016.141

Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/BMT.2016.141

Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/BMT.2016.141

Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/BMT.2016.141

Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/BMT.2016.141

Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/BMT.2016.141

The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/BMT.2016.141

Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI Is the best predictor of NRM and OS in a population of patients underg

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/BMT.2016.141

The hematopoietic cell transplantation-specific comorbidity index (HCT-CI) is an outcome predictor for partially matched related donor transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/BMT.2016.141

Hematopoietic cell transplantation-specific comorbidity index predicts inpatient mortality and survival in patients who received allogeneic transplantation admitted to the intensive care unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/BMT.2016.141

Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/BMT.2016.141

Impact of comorbidity indexes on non-relapse mortality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/BMT.2016.141

A modified EBMT risk score and the hematopoietic cell transplantation-specific comorbidity index for pre-transplant risk assessment in adult acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/BMT.2016.141

Immunohistochemistry of affected tissue may guide cGVHD treatment decisions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/BMT.2016.141

Performance status, but not the hematopoietic cell transplantation comorbidity index (HCT-CI), predicts mortality at a Canadian transplant center.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/BMT.2016.141

Does the hematopoietic cell transplantation specific comorbidity index (HCT-CI) predict transplantation outcomes? A prospective multicenter validation study of the Kanto Study Group for Cell Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/BMT.2016.141

Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/BMT.2016.141

Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/BMT.2016.141

"To combine or not to combine": optimizing risk assessment before allogeneic hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/BMT.2016.141

Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/BMT.2016.141

How I assess comorbidities before hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/BMT.2016.141

Assignment of scores for the hematopoietic cell transplantation comorbidity index: integer vs exact weights

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/BMT.2016.141

Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/BMT.2016.141

Design and Validation of an Augmented Hematopoietic Cell Transplantation-Comorbidity Index Comprising Pretransplant Ferritin, Albumin, and Platelet Count for Prediction of Outcomes after Allogeneic Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/BMT.2016.141

Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/BMT.2016.141

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/BMT.2016.141

Gait speed and survival in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/BMT.2016.141

Prognostic value of physical function tests: hand grip strength and six-minute walking test in elderly hospitalized patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/BMT.2016.141

Hand grip strength and 2-minute walk test in chronic graft-versus-host disease assessment: analysis from the Chronic GVHD Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/BMT.2016.141

Hematopoietic stem cell transplantation rates and long-term survival in acute myeloid and lymphoblastic leukemia: real-world population-based data from the Swedish Acute Leukemia Registry 1997-2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/BMT.2016.141

Review of stem-cell transplantation for myelodysplastic syndromes in older patients in the context of the Decision Memo for Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome emanating from the Centers for Medicare and M

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/BMT.2016.141

Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/BMT.2016.141

Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/BMT.2016.141

Classifying cytogenetics in patients with acute myelogenous leukemia in complete remission undergoing allogeneic transplantation: a Center for International Blood and Marrow Transplant Research study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/BMT.2016.141

Multicenter validation study of a transplantation-specific cytogenetics grouping scheme for patients with myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/BMT.2016.141

Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/BMT.2016.141

Validating the allogeneic stem cell transplantation disease risk index: sample size, follow-up, and local data are important

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/BMT.2016.141

Impact of Pretransplantation (18)F-fluorodeoxy Glucose-Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/BMT.2016.141

Pre-transplant prognostic factors of long-term survival after allogeneic peripheral blood stem cell transplantation with matched related/unrelated donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/BMT.2016.141

Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/BMT.2016.141

Reevaluation of the pretransplant assessment of mortality score after allogeneic hematopoietic transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/BMT.2016.141

Blood and marrow transplant clinical trials network state of the Science Symposium 2014

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/BMT.2016.141

Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/BMT.2016.141

Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/BMT.2016.141

Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/BMT.2016.141

MHC-resident variation affects risks after unrelated donor hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/BMT.2016.141

Discovery and validation of graft-versus-host disease biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/BMT.2016.141

Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/BMT.2016.141

Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/BMT.2016.141

Validation of the disease risk index for outcome of patients undergoing allogeneic hematopoietic stem cell transplantation after T cell depletion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/BMT.2016.141

Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/BMT.2016.141

Validation and extension of the EBMT Risk Score for patients with chronic myeloid leukaemia (CML) receiving allogeneic haematopoietic stem cell transplants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/BMT.2016.141

Predictive impact of allele-matching and EBMT risk score for outcome after T-cell depleted unrelated donor transplantation in poor-risk acute leukemia and myelodysplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/BMT.2016.141

Validation of the EBMT Risk Score for South Brazilian Patients Submitted to Allogeneic Hematopoietic Stem Cell Transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/BMT.2016.141

First application of the EBMT risk score in double umbilical cord blood transplantation for hematologic malignancies: significant impact on different outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/BMT.2016.141

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/BMT.2016.141

The hematopoietic cell transplantation-specific comorbidity index fails to predict outcomes in high-risk AML patients undergoing allogeneic transplantation--investigation of potential limitations of the index

21 January 2018

1 reference

12 December 2020

Peripheral blood or bone marrow cells in reduced-intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma

1 reference

12 December 2020

Pretransplant comorbidities maintain their impact on allogeneic stem cell transplantation outcome 5 years posttransplant: a retrospective study in a single german institution

1 reference

12 December 2020

Role of HCT-comorbidity index, age and disease status at transplantation in predicting survival and non-relapse mortality in patients with myelodysplasia and leukemia undergoing reduced-intensity-conditioning hemopoeitic progenitor cell transplantat

1 reference

12 December 2020

Steroid-refractory GVHD: T-cell attack within a vulnerable endothelial system

1 reference

12 December 2020

Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in older adults

1 reference

12 December 2020

Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia

1 reference

12 December 2020

A risk score for mortality after allogeneic hematopoietic cell transplantation

1 reference

12 December 2020

Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia

1 reference

12 December 2020

The hematopoietic cell transplantation specific comorbidity index and survival after extracorporeal photopheresis, pentostatin, and reduced dose total body irradiation conditioning prior to allogeneic stem cell transplantation

1 reference

12 December 2020

Impact of pretransplant comorbidities on alemtuzumab-based reduced-intensity conditioning allogeneic hematopoietic SCT for patients with high-risk myelodysplastic syndrome and AML

1 reference

12 December 2020

Validation of pretransplantation assessment of mortality risk score in the outcome of hematopoietic SCT in non-Caucasians

1 reference

12 December 2020

EBMT risk score can predict the outcome of leukaemia after unmanipulated haploidentical blood and marrow transplantation

1 reference

12 December 2020

Allo-SCT for AML and MDS with treosulfan compared with BU-based regimens: reduced toxicity vs reduced intensity

1 reference

12 December 2020

EBMT Risk Score Predicts Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Who Have Failed a Previous Transplantation Procedure

1 reference

12 December 2020

Retrospective analysis of common scoring systems and outcome in patients older than 60 years treated with reduced-intensity conditioning regimen and alloSCT

1 reference

12 December 2020

Hematopoietic cell transplantation comorbidity index predicts transplantation outcomes in pediatric patients

1 reference

12 December 2020

A modified comorbidity index for hematopoietic cell transplantation

1 reference

12 December 2020

Differential prognostic impact of pretransplant comorbidity on transplant outcomes by disease status and time from transplant: a single Japanese transplant centre study

1 reference

12 December 2020

Does the hematopoietic cell transplantation specific comorbidity index predict transplant outcomes? A validation study in a large cohort of umbilical cord blood and matched related donor transplants

1 reference

12 December 2020

Validation of the EBMT risk score in chronic myeloid leukemia in Brazil and allogeneic transplant outcome

1 reference

12 December 2020

Allogeneic hematopoietic stem cell transplantation for myelofibrosis

1 reference

12 December 2020

Bone marrow transplantation for acute nonlymphoblastic leukaemia: a survey of the European Group for Bone Marrow Transplantation (E.G.B.M.T.)

1 reference

12 December 2020

Identifiers

DOI

10.1038/BMT.2016.141

1 reference

Dimensions Publication ID

7 September 2017

1032677234

0 references

1 reference